Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hannan, P. C. T.
Right arrow Articles by Woodnutt, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hannan, P. C. T.
Right arrow Articles by Woodnutt, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 367-369
© 2000 The British Society for Antimicrobial Chemotherapy

Brief reports

In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas

Peter C. T. Hannana,* and Gary Woodnuttb

a Mycoplasma Experience Ltd, 1 Norbury Road, Reigate RH2 9BY, UK; b SmithKline Beecham Pharmaceuticals, 1250 South Collegeville Road, PO Box 5089, Collegeville, PA 19426-0989, USA

The in vitro activity of gemifloxacin, a new broad-spectrum fluoroquinolone, was compared with those of ciprofloxacin, erythromycin, azithromycin and doxycycline against 29 human respiratory or urogenital tract mycoplasmas. Gemifloxacin was highly active against all of the mycoplasma and ureaplasma species tested (MIC range 0.001–0.25 mg/L) and was 5- to 100-fold more active than ciprofloxacin. Doxycycline was less active than gemifloxacin against the mycoplasmas (MIC range 0.01–1 mg/L) but had similar activity against Ureaplasma urealyticum (MIC ranges 0.025–0.25 mg/L and 0.1–0.25 mg/L, respectively). The macrolides, particularly azithromycin, were more active than gemifloxacin against Mycoplasma pneumoniae (MIC range 0.001–0.0025 mg/L) and Mycoplasma genitalium (0.0005–0.001 mg/L) isolates but were less active against Mycoplasma fermentans and U. urealyticum and inactive against Mycoplasma hominis. Gemifloxacin may therefore be useful in the treatment of respiratory, urogenital or systemic mycoplasma infections in humans.

* Corresponding author. Tel: +44-1737-226662; Fax: +44-1737-224751.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Int J STD AIDSHome page
E Jernberg, A Moghaddam, and H Moi
Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study
Int J STD AIDS, October 1, 2008; 19(10): 676 - 679.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Pereyre, H. Renaudin, C. Bebear, and C. M. Bebear
In Vitro Activities of the Newer Quinolones Garenoxacin, Gatifloxacin, and Gemifloxacin against Human Mycoplasmas
Antimicrob. Agents Chemother., August 1, 2004; 48(8): 3165 - 3168.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. B. Waites, D. M. Crabb, X. Bing, and L. B. Duffy
In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas
Antimicrob. Agents Chemother., January 1, 2003; 47(1): 161 - 165.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.